ACADIA Pharmaceuticals Inc.: Psychotic Disorders trials

The registry lists 11 Psychotic Disorders studies with ACADIA Pharmaceuticals Inc. as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 3Phase 3 5Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisCompletedNCT04292223Phase 4Results posted
• Relapse Prevention Study of Pimavanserin in Dementia-related PsychosisCompletedNCT03325556Phase 3Results posted
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease PsychosisCompletedNCT02035553Phase 2Results posted
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedNCT01174004Phase 3Results posted
• A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00658567Phase 3Results posted
• A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00550238Phase 3Results posted
• A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00477672Phase 3Results posted
• The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) StudyTerminatedNCT03152292
• Expanded Access of Pimavanserin for Patients With PD PsychosisApproved for marketingNCT02762591
• ACP-104 in Acutely Psychotic Subjects With SchizophreniaCompletedNCT00490516Phase 2
• Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational DrugCompletedNCT00087542Phase 2